Unlike the Swiss peers, Novo Nordisk reported healthy Q3 sales and operating profit growth, which also resulted in a 2020 guidance upgrade. Product-wise, this outperformance was driven by GLP-1, which more than offset the sustained erosion in insulins. Geographically, IO led from the front (across various categories) and helped compensate for sluggishness in the all-important US market. Overall, while business-performance-wise, Novo continues to do well, a further re-rating will have to await ma ....
04 Nov 2020
Healthy Q3 growth (driven by GLP-1 and International Operations)
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Healthy Q3 growth (driven by GLP-1 and International Operations)
Novo Nordisk A/S Class B (NNO2:WBO), 0 | Novo Nordisk A/S Class B (NOV:BRN), 0 | Novo Nordisk A/S Class B (NOV:ETR), 0 | Novo Nordisk A/S Class B (NOVO.B:CSE), 0 | Novo Nordisk A/S Class B (0QIU:LON), 0 | Novo Nordisk A/S Class B (NONOF:OTC), 0
- Published:
04 Nov 2020 -
Author:
Surbhit Gupta -
Pages:
5
Unlike the Swiss peers, Novo Nordisk reported healthy Q3 sales and operating profit growth, which also resulted in a 2020 guidance upgrade. Product-wise, this outperformance was driven by GLP-1, which more than offset the sustained erosion in insulins. Geographically, IO led from the front (across various categories) and helped compensate for sluggishness in the all-important US market. Overall, while business-performance-wise, Novo continues to do well, a further re-rating will have to await ma ....